Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Roche wins FDA approval for hepatitis C viral load test
The test uses Roche’s real-time polymerase chain reaction technology to quantify the amount of hepatitis C RNA in a patient’s blood. The new test offers a broad dynamic
The test uses Roche’s real-time polymerase chain reaction technology to quantify the amount of hepatitis C RNA in a patient’s blood. The new test offers a broad dynamic
The license agreement also includes Monebo’s call center management software. Bioheart plans to immediately begin selling the CardioBelt system worldwide, including the US market, as a complementary technology
Final results from the study confirmed the positive interim results announced in July 2008 that significantly higher anti-nicotine antibody levels can be generated three months earlier and in
In this study, designed to show equivalent rate of change in bone mineral density (BMD) for Advair and salmeterol, results for bone mineral density in the lumbar spine
In this study, researchers found that Vyvanse controlled attention deficit hyperactivity disorder (ADHD) symptoms from the first time point measured (1.5 hours) through the last time point assessed
The company has also requested priority review, based on the potential for PolyHeme to address a critical, unmet medical need. By regulation, the FDA has 60 calendar days
The Flair endovascular stent graft, comprised of a self-expanding nitinol stent encapsulated within Bard’s proprietary ePTFE graft material, is marketed by the Bard Peripheral Vascular division located in
The regulatory application included a study that validated the performance of the TearLab osmolarity system when performed in physician office laboratories by health care professionals using human tear
In the trial, two concentrations (0.5% and 1%) of WBI-1001 were tested against the placebo. Both WBI-1001 cream concentrations were superior to placebo in deceasing atopic dermatitis (AD)
The trial results confirmed that single doses of up to 1,800mg of ALV003 were safe and tolerable in healthy volunteers. Doses at the 300mg level achieved up to